Skip to main content
. 2020 Jun 3;15(6):e0233595. doi: 10.1371/journal.pone.0233595

Fig 2. Mean change in visual acuity by injection frequency in treatment-naïve patients with DME (N = 502; primary treated eye set).

Fig 2

Observed dataset for VA change. The primary treated eye set included all primary treated eyes in patients included in the safety set. The safety set consisted of patients in the enrolled set who were treated with at least one dose of ranibizumab during this study or prior to the start of the study and had at least one safety assessment after the first treatment. For treatment-naïve eyes, the date of first on-study injection with ranibizumab was considered the baseline date. For the 1-year time period, all patients with non-missing baseline VA and year 1 VA performed anywhere between Day 319 and Day 409 but who had been in the study for at least 365 days from baseline to last follow-up date were included in the analysis. DME, diabetic macular edema; ETDRS, Early Treatment Diabetic Retinopathy Study; VA, visual acuity.